Jade Biosciences, Inc. (JBIO)
Data as of , from SEC Form 4 filings.
See up to 3 months of JBIO. The 7-day demo opens the 1M and 3M ranges and puts JBIO on your watchlist.
Start 7-day demoLatest JBIO insider trades
About Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc. files with the SEC under CIK 0001798749 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site. It filed a registration statement with the SEC on 14 November 2025 and has not yet priced an offering.
JBIO Form 4 activity by transaction type, last 90 days
No Form 4 activity for JBIO in the last 90 days.
JBIO insider transactions (Form 4)
1813 Form 4 filings on record, the earliest from Apr 29, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mark Eisner | Grant or award | Stock Option (Right to Buy) | 47,675 | $0.00 | - | |
| Christopher W. Cain | Grant or award | Stock Option (Right to Buy) | 34,843 | $0.00 | - | |
| Eric Dobmeier | Grant or award | Stock Option (Right to Buy) | 34,843 | $0.00 | - | |
 Lawrence Otto Klein | Grant or award | Stock Option (Right to Buy) | 34,843 | $0.00 | - | |
| Erin Lavelle | Grant or award | Stock Option (Right to Buy) | 34,843 | $0.00 | - | |
| Fairmount Funds Management LLC | Grant or award | Stock Option (Right to Buy) | 34,843 | $0.00 | - | |
| Bradford D. Dahms - Officer | Grant or award | Common Stock | 37,813 footnote F1 | $0.00 | - | |
| Bradford D. Dahms - Officer | Grant or award | Stock Option (Right to Buy) | 226,875 | $0.00 | - | |
| ||||||
| Elizabeth Balta - Officer | Grant or award | Common Stock | 28,125 footnote F1 | $0.00 | - | |
| Elizabeth Balta - Officer | Grant or award | Stock Option (Right to Buy) | 168,750 | $0.00 | - | |
| ||||||
| Tom Frohlich - Officer | Grant or award | Common Stock | 78,750 footnote F1 | $0.00 | - | |
| Tom Frohlich - Officer | Grant or award | Stock Option (Right to Buy) | 472,500 | $0.00 | - | |
| ||||||
| Andrew James King - Officer | Grant or award | Common Stock | 41,250 footnote F1 | $0.00 | - | |
| Andrew James King - Officer | Grant or award | Stock Option (Right to Buy) | 247,500 | $0.00 | - | |
| ||||||
| Fairmount Funds Management LLC - Director | Grant or award | Common Stock | 1,333,126 | $9.14 | $12.18M | |
| Fairmount Funds Management LLC - Director | Grant or award | Pre-Funded Warrant (Right to Buy) | 855,047 | $9.14 | $7.82M | |
| Bradford D. Dahms - Officer | Grant or award | Stock Option (Right to Buy) | 526,000 | $0.00 | - | |
| Eric Dobmeier | Grant or award | Stock Option (Right to Buy) | 23,017 | $0.00 | - | |
JBIO insider trading FAQ
What is the latest insider trade for JBIO?
Jade Biosciences, Inc. (JBIO) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-27. The full record for JBIO runs to 13 Form 4 filings, the earliest from 2025-04-29. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying JBIO stock?
No insider purchases of JBIO were filed in the last 90 days.
How many insiders are selling JBIO stock?
No insider sales of JBIO were filed in the last 90 days.
Where can I see JBIO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects JBIO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Mark Eisner view on EDGAR
- - Christopher W. Cain view on EDGAR
- - Eric Dobmeier view on EDGAR
- - Lawrence Otto Klein view on EDGAR
- - Erin Lavelle view on EDGAR
- - Fairmount Funds Management LLC view on EDGAR
- - Bradford D. Dahms view on EDGAR
- - Elizabeth Balta view on EDGAR
- - Tom Frohlich view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where JBIO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow JBIO with a 7-day demo
- JBIO on your watchlist
- Every JBIO Form 4 filing on record
- Up to 3 months of JBIO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
